OX40L and IL-2 combination strategy for gastric cancer immunotherapy
Benshun Hu, Emanuela Garbarino, Jingjing Ma, Chengyuan Yan, Junli Jia, Hua Xie, Lingyun Li, Cheng Jin, Yuzheng Xue, Huamin Tang · 2025
Read OX40L and IL-2 combination strategy for gastric cancer immunotherapy by Benshun Hu, Emanuela Garbarino, Jingjing Ma, Chengyuan Yan, Junli Jia, Hua Xie, Lingyun Li, Cheng Jin, Yuzheng Xue, Huamin Tang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12776187.txt.
Description
Benshun Hu and co-authors test a paired immune strategy for gastric cancer, in a research paper from 2025. The cancer is often found late, and remission rates stay low. The tumor setting suppresses immune attack, with weak T-cell activation and weak co-stimulatory signals, so standard drugs help only in part.
The pair joins interleukin-2 with OX40 ligand, two signals that rouse T cells. The team mapped their patterns in tumor tissue and in immune cells from patients. A virus vector carrying both signals boosted T-cell killing of tumor cells in lab tests. The work supports paired stimulation as a path to stronger immune care.
Catalog record
| CREATOR | Benshun Hu, Emanuela Garbarino, Jingjing Ma, Chengyuan Yan, Junli Jia, Hua Xie, Lingyun Li, Cheng Jin, Yuzheng Xue, Huamin Tang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |